



Attorney Docket No.: UBC.P-030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gleave et al.
Serial No.: 10/646,436
Confirmation: 9171
Filed: August 21, 2003
Title: RNAi Probes Targeting Cancer-Related Proteins

SUBMISSION OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith.

No fee is believed to be due with this paper as we have not received an action on the merits. The Commissioner is authorized to charge any fees which may be due to Deposit Account Number 15-0610.

Respectfully submitted,
OPPEDAHL & LARSON LLP

Marina Larson
Marina T. Larson, PhD, Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
Ph: 970-468-6600 / Fax: 970-468-0104

CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on March 29, 2004

3-29-04
Date of Signature

Lori A. South
Lori South



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Under the Patent Act of 1990, no persons are required to respond to a collection of information unless it displays a valid OMB control number.</p> <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
Sheet	1	of	4	Application Number	10/646,436
				Filing Date	8/21/2003
				First Named Inventor	Gleave et al.
				Art Unit	1645
				Examiner Name	
				Attorney Docket Number	UBC.P-030

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

4

Complete it. Know it.

Application Number	10/646,436
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1645
Examiner Name	

Attorney Docket

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/646,436
Sheet	2	of	4	Filing Date	8/21/2003
				First Named Inventor	Gleave et al.
				Art Unit	1645
				Examiner Name	
				Attorney Docket Number	UBC.P-030

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AGAMI , RNAi and related mechanisms and their potential use for therapy, Current Opinion in Chemical Biology, 2002, Page(s) 829-834, Volume 6, Publisher: Current Biology Ltd, London, GB XP00295888	
		BRUMMELKAMP ET AL., A system for stable expression of short interfering RNAs in mammalian cells, Science, 2002, Page(s) 550-553, Volume 296, Number 5567, Publisher: American Association for the Advancement of Science, US, XP002234902	
		CALERO ET AL., Apolipoprotein J (Clusterin) and Alzheimer's Disease, Microscopy Research and Technique, 2000, Page(s) 305-315, Volume 50, Number 4, XP009021345	
		CHOI-MIURA ET AL., Relationship Between Multifunctional Protein "Clusterin" and Alzheimer Disease, Neurobiology of Aging, 1996, Page(s) 717-722, Volume 17, Number 5, XP001146408	
		DEMIR ET AL., Use of RNA Interference (RNAi) to Disrupt C-Kit Gene Expression in Malignant Human Hematopoietic and Neuroepithelial Cells, Blood, 2000, Page(s) 378B, Volume 96, Number 11, Part 2, Publisher: W. B. Saunders Company, Orlando, FL, US, Abstract #5389, XP009004894	
		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58, XP002262320	
		GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Number 2, XP 009021411	
		HOJOH , RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells, FEBS Letters, 2002, Page(s) 195-199, Volume 521, Number 1-3, Publisher: Elsevier Science Publishers, Amsterdam, NL XP004362164	
		JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34, XP002262319	
		KOCH-BRANDT ET AL., Clusterin: A Role in Cell Survival in the Face of Apoptosis?, Process in Molecular and Subcellular Biology, 1996, Page(s) 130-149, Volume 16, XP009021385	
		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, Page(s) 1655-1663, Volume 6, Number 5, Publisher: The American Association for Cancer Research, US, XP000960694	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/646,436
		<i>Filing Date</i>	8/21/2003
		<i>First Named Inventor</i>	Gleave et al.
		<i>Art Unit</i>	1645
		<i>Examiner Name</i>	
Sheet	(Use as many sheets as necessary) of	Attorney Docket Number	UBC.P-030

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity., International Journal of Urology, 2001, Page(s) 337-349, Volume 8, Number 7, XP002262321		
		PADDISON ET AL., Stable suppression of gene expression by RNAi in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, Page(s) 1443-1448, Volume 99, Number 3, Publisher: National Academy of Science, XP002958887		
		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, Page(s) 633-645, Volume 27, Number 7, XP001002844		
		SENSIBAR ET AL., Prevention of Cell Death Induced by Tumor Necrosis Factor α in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin), Cancer Research, 1995, Page(s) 2431-2437, Volume 55, Publisher: American Association for Cancer Research, Baltimore, MD, US, XP002930082		
		SHARP, RNAi and double-strand RNA, Genes and Development, 1999, Page(s) 139-141, Volume 13, Number 2, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002171268		
		STROCCHI ET AL., Neuronal loss up-regulates clusterin mRNA in living neurons and glial cells in the rat brain, NeuroReport, 1999, Page(s) 1789-1792, Volume 10, Number 8, Publisher: Rapid Communications of Oxford, Oxford, GB, XP009017327		
		SUI ET AL., A DNA vector-based RNAi technology to suppress gene expression in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, Page(s) 5515-5520, Volume 99, Number 8, Publisher: National Academy of Science, Washington, US, XP002964701		
		TUSCHL ET AL., Targeted mRNA degradation by double-stranded RNA in vitro, Genes and Development, 1999, Page(s) 3191-3197, Volume 13, Number 24, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002183118		
		UEDA , RNAi: A new technology in the post-genomic sequencing era, Journal of Neurogenetics, 2001, Page(s) 193-204, Volume 15, Number 3/4, Publisher: Elsevier, Amsterdam, NL, XP001147227		
		WILSON ET AL., Clusterin is a secreted mammalian chaperone, Trends in Biochemical Sciences, 2000, Page(s) 95-98, Volume 25, No. 3, Publisher: Elsevier Publication, Cambridge, EN, XP004202536		
		WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, Page(s) 917-925, Volume 227, Number 3, XP 001146404		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Application Number</i>	10/646,436
		<i>Filing Date</i>	8/21/2003
		<i>First Named Inventor</i>	Gleave et al.
		<i>Art Unit</i>	1645
		<i>Examiner Name</i>	
Sheet	4	of	4
		<i>Attorney Docket Number</i>	UBC.P-030

NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.